- Home
- RADX vs FBRX Comparison
RADX vs FBRX Comparison
Compare RADX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- FBRX
- Stock Information
- Founded
- RADX 2021
- FBRX N/A
- Country
- RADX Australia
- FBRX United States
- Employees
- RADX N/A
- FBRX N/A
- Industry
- RADX
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- RADX
- FBRX Health Care
- Exchange
- RADX NYSE
- FBRX Nasdaq
- Market Cap
- RADX 31.8M
- FBRX 35.3M
- IPO Year
- RADX N/A
- FBRX N/A
- Fundamental
- Price
- RADX $3.91
- FBRX $6.34
- Analyst Decision
- RADX Strong Buy
- FBRX Strong Buy
- Analyst Count
- RADX 2
- FBRX 3
- Target Price
- RADX $13.50
- FBRX $80.50
- AVG Volume (30 Days)
- RADX 29.1K
- FBRX 27.8K
- Earning Date
- RADX 02-26-2025
- FBRX 05-20-2025
- Dividend Yield
- RADX N/A
- FBRX N/A
- EPS Growth
- RADX N/A
- FBRX N/A
- EPS
- RADX N/A
- FBRX N/A
- Revenue
- RADX $204,609.00
- FBRX N/A
- Revenue This Year
- RADX N/A
- FBRX N/A
- Revenue Next Year
- RADX N/A
- FBRX N/A
- P/E Ratio
- RADX N/A
- FBRX N/A
- Revenue Growth
- RADX N/A
- FBRX N/A
- 52 Week Low
- RADX $3.50
- FBRX $4.11
- 52 Week High
- RADX $50.82
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- FBRX 45.09
- Support Level
- RADX N/A
- FBRX $6.13
- Resistance Level
- RADX N/A
- FBRX $6.75
- Average True Range (ATR)
- RADX 0.00
- FBRX 0.73
- MACD
- RADX 0.00
- FBRX -0.01
- Stochastic Oscillator
- RADX 0.00
- FBRX 51.79
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).